Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2003-03-24
2009-12-08
Kosar, Andrew D (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S017400, C514S018700, C514S019300, C530S329000, C530S330000, C530S331000, C530S332000, C530S333000
Reexamination Certificate
active
07629318
ABSTRACT:
The present invention relates to compositions and methods for suppressing an immune response, e.g., by inhibiting class II MHC-mediated activation of T cells. The subject compounds and methods may be used to treat or prevent disorders such as rheumatoid arthritis and/or multiple sclerosis.
REFERENCES:
patent: WO-96/19483 (1996-06-01), None
patent: WO-96/37497 (1996-11-01), None
patent: WO-97/48687 (1997-12-01), None
patent: WO-97/48706 (1997-12-01), None
patent: WO-98/09987 (1998-03-01), None
patent: WO-98/28326 (1998-07-01), None
patent: WO-99/61476 (1999-12-01), None
patent: WO-00/78796 (2000-12-01), None
patent: WO-01/27141 (2001-04-01), None
S. Feng and S.L. Schreiber. J. Am. Chem. Soc. (1997) 119, pp. 10873-10874.
Q. Xu et al. Biochemistry. (1999) 38, pp. 3491-3497.
Christensen, H. N., et al., “Synthesis of Metabolism-Resistant Substrates for the Transport System for Cationic Amino Acids;Their Stimulation of the Release of Insulin and Glucagon, and of the Urinary Loss of Amino Acids Related to Cystinuria,” Biochimica et Biophysica Acta,, 298:932-950 (1973).
Cunningham, B.R., et al., “SAR For MHC Class II Binding Tetrapeptides: Correlation With Potential Binding Site,” Bioorganic & Medicinal Chemistry Letters, 7(1):19-24 (1997).
Falcioni, F., et al., “Peptidomimetic compounds that inhibit antigen presentation by autoimmune disease-associated class II major histocompatibility molecules,” Nature Biotechnology, 17:562-567 (1999).
Hanson, G.J., et al., “Design of MHC Class II (DR4) Ligands Using Conformationally Restricted Imino Acids at p3 and p5,” Bioorganic & Medicinal Chemistry Letters, 6(16):1931-1936 (1996).
Jones, A.B., et al., “Tetrapeptide Derived Inhibitors of Complexation of a Class II MHC: Fully Unnatural Ligands,” Bioorganic & Medicinal Chemistry Letters, 9:2115-2118 (1999).
Jones, A.B., et al., “Tetrapeptide Derived Inhibitors of Complexation of a Class II MHC: The Peptide Backbone is not Inviolate,” Bioorganic & Medicinal Chemistry Letters, 9:2109-2114 (1999).
Kent, D. R., et al., “Synthesis of 3-(3-pyrrolidinyl)alanine and its derivatives as arginine peptidomimetics for incorporation into serine protease inhibitors,” Pept. Proc. Am. Pept,. Symp., 15th (1999), Meeting Date 1997, 688-689.
Plummer, J. S., et al., “Potent and Selective Bicyclic Lactam Inhibitors of Thrombin: Part 2: P1 Modifications,” Bioorganic & Medicinal Chemistry Letters, 8:3409-3414 (1998).
Schmidt, M.A., et al., “Increased serum stability of neurotensin analogs containing arginine mimics,” (2000) Pept. New Milennium, Proc Am Pept. Symp 634-635 (use of Gpg to stabiles neurotensin peptides).
St. Laurent, D. R., et. al., “Active Site-directed Thrombin Inhibitors—II. Studies Related to Arginine/Guanidine Bioisosteres,” Bioorganic & Medicinal Chemistry, 3(8):1145-1156 (1995).
Tamura, S.Y., et al., “Guanylpiperidine Peptidomimetics: Potent and Selective bis-Cation Inhibitors of Factor Xa,” Bioorganic & Medicinal Chemistry Letters, 10:745-749 (2000).
Brandstetter Tilmann
Nagy Zoltan
GPC Biotech AG
Kosar Andrew D
O'Brien David G.
Yankwich Leon R.
Yankwich & Associates P.C.
LandOfFree
Immunosuppressant compounds, methods and uses related thereto does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunosuppressant compounds, methods and uses related thereto, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunosuppressant compounds, methods and uses related thereto will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4120630